Stock analysis, trade plans, and proprietary indicators by Trend Edge.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is… Read full Trend Edge analysis →
| Current Price | $4.41 |
|---|---|
| Market Cap | $1.54B |
| Float | 297.1M |
| Shares Outstanding | 368.2M |
| Price/Sales (TTM) | 441.74 |
| vs. Analyst Target | +217.5% to analyst PT |
| Operating Margin (TTM) | -3239.10% |
| Revenue (TTM) | $3.5M |
| Earnings Growth (YoY) | -96.80% |
| Dividend Rate | None |
| Analyst Target Price | $14.00 (7 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | $19.9M | -$170M | -$24,000 | -$92.1M |
| 2021 | $20.4M | -$168M | $20.4M | -$120M |
| 2022 | $233,000 | -$152M | $233,000 | -$144M |
| 2023 | $314,000 | -$40.2M | $314,000 | -$122M |
| 2024 | $308,000 | -$149M | $308,000 | -$99.3M |
| 2025 | $4.1M | -$660M | $4.1M | -$658M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Jun 2025 | $719,000 | -$27.7M |
| Sep 2025 | $749,000 | -$61.1M |
| Dec 2025 | $1.1M | -$545M |
| Mar 2026 | $953,999 | -$29.8M |
| Insider Ownership | 2.4% |
|---|---|
| Institutional Ownership | 43.5% |
| Short Float | 7.7% |
| % of All Funds Holding | 2.03% |
| Number of Funds Holding | 167 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $4.04 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $4.25 | Medium-term trend |
| Weekly | 80-Week SMA | $3.17 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $2.43 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $4.32 | Near-term monthly trend |
| Monthly | 20-Month SMA | $3.10 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $2.35 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $2.70 | support | 3.34x | 9 months ago |
| $1.50 | support | 1.22x | 11 months ago |
| $1.10 | support | 1.97x | 17 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 0.73% | 0.56% | 55.00% | 6.62% | -3.87% |
| 1 Day | 2.13% | 1.83% | 55.00% | 14.75% | -13.87% |
| 1 Week | 5.34% | -3.57% | 45.00% | 52.10% | -25.13% |
| 2 Weeks | 7.69% | 0.43% | 50.00% | 60.42% | -26.41% |
| 1 Month | 2.69% | -2.31% | 47.37% | 57.14% | -49.20% |
Next earnings: July 31, 2026 (62 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | 0.34% | 47.8% | 230 |
| Tuesday | 0.17% | 45.5% | 257 |
| Wednesday | -0.14% | 43.3% | 254 |
| Thursday | -0.28% | 42.9% | 247 |
| Friday | -0.00% | 45.2% | 250 |
Institutional holder breakdown coming soon.
Total institutional ownership: 43.5%
Total insider ownership: 2.4%
Founder-led management: Christian Angermayer (Co-Founder & Chairman of the Board), Srinivas G. Rao (Co-Founder, CEO & Executive Director)
| Total Filings | 4 |
|---|---|
| Net Value | -$373,213.346 |
| Net Shares Change | 8,636,205 |
| % of Float | 2.9% |
| C-Suite Filings | 2 |
| Clusters Detected | 0 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Apeiron Investment Group Ltd. | +$19.0M | 1 | 1 buy | |
| Craig Kevin James | Chief Medical Officer | -$373,213.346 | 2 | N/A |
| Feilding-Mellen Cosmo | -$154,377.006 | 1 | 1 sell |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2025-08-18 | Apeiron Investment Group Ltd. | +$19.0M | Transaction at $2.19, now +101.4% | |
| 2026-01-06 | Feilding-Mellen Cosmo | -$154,377.006 | Transaction at $3.90, now +13.1% | |
| 2026-04-22 | Craig Kevin James | Chief Medical Officer | -$143,823.346 | Transaction at $3.31, now +33.2% |
| 2026-03-24 | Craig Kevin James | Chief Medical Officer | -$229,390 | Transaction at $2.40, now +83.5% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for ATAI Life Sciences BV (ATAI) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for ATAI on Trend Edge →